Data Sheet 3_Comparison of probiotics to lactulose for minimal hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.pdf

BackgroundMinimal hepatic encephalopathy (MHE) represents a reversible, early-stage form of hepatic encephalopathy (HE). Although probiotics have been extensively studied for MHE management, direct comparative evidence against standard lactulose therapy remains limited. This meta-analysis aimed to quantitatively evaluate the relative efficacy and safety of probiotics versus lactulose in cirrhotic patients with MHE.
MethodsPubMed, the Cochrane Library, Embase, Web of Science, and the Chinese Biomedical Literature Database (CBM) were systematically searched from inception to August 2025 to identify randomized controlled trials (RCTs) comparing probiotics with lactulose for the treatment of MHE in patients with cirrhosis. Extracted outcomes included MHE reversal, overt hepatic encephalopathy (OHE) development, serum ammonia reduction, and adverse events (AEs).
ResultsFive studies involving 345 cirrhotic patients were included. Pooled analyses showed no statistically significant differences between probiotics and lactulose in reversing MHE (RR: 0.98, 95% CI: 0.79–1.20; p = 0.822), preventing OHE development (RR: 1.40, 95% CI: 0.75–2.61; p = 0.289), and reducing serum ammonia levels (SMD: −0.05, 95% CI: −0.29 to 0.19; p = 0.678). In contrast, probiotics were associated with a significantly lower incidence of AEs compared with lactulose (RR: 0.17, 95% CI: 0.05–0.60; p = 0.005).
ConclusionThis meta-analysis found no evidence that probiotics are superior or inferior to lactulose in terms of MHE reversal, prevention of OHE, and reduction of serum ammonia levels. Probiotics were associated with fewer AEs, suggesting a potential safety advantage. Further large-scale, high-quality RCTs are warranted to confirm these findings.